Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

MDGL earnings analysis

Filed May 6, 2026 · Our reading of the company's report

The latest report

Madrigal Pharmaceuticals reported Q1 2026 financials with strong revenue growth, achieving $311.3 million, reflecting a 127% increase from Q1 2025's $137.3 million. The company recorded a net loss of $94.4 million, up…

Read full summary

Madrigal Pharmaceuticals reported Q1 2026 financials with strong revenue growth, achieving $311.3 million, reflecting a 127% increase from Q1 2025's $137.3 million. The company recorded a net loss of $94.4 million, up from $73.2 million in the year-ago period, while expanding its cash position to $817.9 million despite significant operating costs related to the commercialization of its product Rezdiffra. Management remains optimistic about the adoption and growth potential of Rezdiffra in the market.

Read the original on SEC.gov

Reported figures

Earnings per share
$-3.25

What stood out

  • Revenue Growth Accelerates

    Q1 2026 revenue was $311.3 million, a 127% increase from $137.3 million in Q1 2025.

  • Improving Cash Position

    Cash and cash equivalents increased to $227.0 million from $198.7 million quarter-over-quarter.

  • Strong Adoption of Rezdiffra

    Product sales of Rezdiffra significantly drove the revenue increase, resulting in a strong market presence.

  • Segment Performance

    Research and Development expenses surged 146% to $108.7 million attributed to pipeline expansion.

  • Lower Losses Per Share

    Reported EPS loss of $3.25, improved from a loss of $2.61 in Q1 2025.

  • Operating Cash Flow Trends

    Net cash used in operating activities reached $167.4 million, reflecting increased spending on commercialization.

What to watch

  • High Operating Expenses

    Operating expenses rose to $404.1 million from $216.6 million in Q1 2025, indicating cost challenges.

  • Significant Losses Persist

    Net loss increased by 29% year-over-year, now at $94.4 million for Q1 2026.

  • Dependence on Rezdiffra Adoption

    Continued losses and financing needs hinge on successful market uptake of Rezdiffra.

Management's outlook

Outlook deferred to earnings press release / call.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.